Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions, Inc. (NASDAQ: BLFS) is a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. News about BLFS often centers on how its biopreservation media, CellSeal vials, hPL products, and related cell processing tools are used in clinical trials and commercial CGT therapies, as well as on portfolio changes and strategic transactions.
Investors and industry followers can use this page to track BioLife’s announcements on quarterly and annual financial results, including updates on Cell Processing revenue and the performance of its biopreservation media franchise. The company regularly reports on the contribution of customers with approved therapies, the extent of clinical trial adoption in the United States, and its use of GAAP and non-GAAP measures such as adjusted gross margin and adjusted EBITDA.
BioLife’s news flow also includes updates on portfolio streamlining and strategic moves, such as the divestiture of its evo cold chain logistics subsidiary and earlier sales of Global Cooling, SciSafe, and Custom Biogenic Systems, as well as acquisitions and investments like the PanTHERA CryoSolutions IRI cryopreservation technology and the strategic investment in Pluristyx. These items illustrate how the company is focusing on its core cell processing business while adding scientific capabilities and adjacencies.
In addition, BioLife issues press releases on corporate developments such as the opening of the Aby J. Mathew Center for Biopreservation Excellence in Bothell, Washington, and participation in healthcare and small- and mid-cap investor conferences. For readers following the CGT supply chain, this news page provides a centralized view of BioLife’s operational updates, clinical adoption metrics, strategic transactions, and investor communications over time.
Summary not available.
BioLife Solutions (BLFS) reported strong financial results for Q2 2020, achieving $9.9 million in total revenue, a 48% increase from Q2 2019. Biopreservation media revenue rose to $6.7 million, comprising 67% of total revenue despite a 23% decline from Q1 2020. The company gained 88 new customers and processed 14 new U.S. FDA Drug Master File requests. However, net loss for Q2 was $16.4 million due to expenses related to warrants. The company has sufficient cash reserves of $29.9 million for strategic acquisitions. Financial guidance for 2020 remains withdrawn.
BioLife Solutions (NASDAQ: BLFS) will release its second quarter 2020 financial results on August 6, 2020, after market close. A conference call and live webcast will occur at 4:30 p.m. ET, where management will discuss the financial results and company updates. BioLife specializes in bioproduction tools for cell and gene therapies, including products like CryoStor® and HypoThermosol®. Investors can access the webcast via the company’s Investor Relations page.
BioLife Solutions announced the closing of its public offering of 5,951,250 shares of common stock at $14.50 per share, grossing approximately $86 million before deductions. This includes the underwriters' full exercise option for an additional 776,250 shares. Cowen, Oppenheimer & Co., and Stephens Inc. served as joint book-running managers, with B. Riley FBR, Maxim Group LLC, and Northland Capital Markets as co-managers. The offering was made under an SEC registration statement and all relevant documents are available on their website.
BioLife Solutions, a provider of bioproduction tools for cell and gene therapies, has priced a public offering of 5,175,000 shares at $14.50 each, generating approximately $75 million in gross proceeds. The offering is set to close on July 7, 2020, pending closing conditions. Furthermore, underwriters have a 30-day option for an additional 776,250 shares. The proceeds will be used for general corporate purposes, including potential investments in synergistic companies.
BioLife Solutions, based in Bothell, Wash., announced preliminary revenue estimates for Q2 2020, projecting between $9.6 million and $9.8 million, which reflects a 43% to 46% growth compared to the same period in 2019. CEO Mike Rice highlighted the addition of 57 new customers and the use of their products in 23 new clinical trials despite challenges from COVID-19. The revenue figures are preliminary and subject to further review by independent auditors.
BioLife Solutions (NASDAQ: BLFS) announced a proposed public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares offered. The offering is subject to market conditions and there's no guarantee of completion. Proceeds will be used for general corporate purposes, including potential investments or acquisitions that complement BioLife's technology. Cowen, Oppenheimer & Co., and Stephens Inc. will manage the offering. All shares will be offered under an effective shelf registration statement filed with the SEC.